Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A DORIA

Showing results (371-380 of 667) with videos related to

Pageof 67
Sort By:
Cell Reports|January 30, 2026
Vaccine elicitation of HIV-1 neutralizing antibodies against both V2 apex and fusion peptide in rhesus macaquesHongying Duan, Joseph P Nkolola, Shuishu Wang, et al.
Biorxiv : the Preprint Server for Biology|November 21, 2023
Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman PrimatesMatthew Gagne, Barbara J Flynn, Shayne F Andrew, et al.
Nature Immunology|September 3, 2024
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primatesMatthew Gagne, Barbara J Flynn, Shayne F Andrew, et al.
Nature|March 5, 2014
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodiesNicole A Doria-Rose, Chaim A Schramm, Jason Gorman, et al.
Biorxiv : the Preprint Server for Biology|April 5, 2022
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clonesNoemia S Lima, Maryam Musayev, Timothy S Johnston, et al.
Nature Medicine|June 6, 2018
Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1Kai Xu, Priyamvada Acharya, Rui Kong, et al.
The Lancet. HIV|May 23, 2025
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adultsRichard L Wu, Katherine V Houser, Martin R Gaudinski, et al.
Cell|May 26, 2015
Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 DonorsTongqing Zhou, Rebecca M Lynch, Lei Chen, et al.
Nature Communications|December 14, 2022
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clonesNoemia S Lima, Maryam Musayev, Timothy S Johnston, et al.
Nature Medicine|February 5, 2020
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorVincent Dussupt, Rajeshwer S Sankhala, Gregory D Gromowski, et al.
Pageof 67

Showing results (371-380 of 667) with videos related to

Sort By:
Pageof 67
Cell Reports|January 30, 2026
Vaccine elicitation of HIV-1 neutralizing antibodies against both V2 apex and fusion peptide in rhesus macaquesHongying Duan, Joseph P Nkolola, Shuishu Wang, et al.
Biorxiv : the Preprint Server for Biology|November 21, 2023
Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman PrimatesMatthew Gagne, Barbara J Flynn, Shayne F Andrew, et al.
Nature Immunology|September 3, 2024
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primatesMatthew Gagne, Barbara J Flynn, Shayne F Andrew, et al.
Nature|March 5, 2014
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodiesNicole A Doria-Rose, Chaim A Schramm, Jason Gorman, et al.
Biorxiv : the Preprint Server for Biology|April 5, 2022
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clonesNoemia S Lima, Maryam Musayev, Timothy S Johnston, et al.
Nature Medicine|June 6, 2018
Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1Kai Xu, Priyamvada Acharya, Rui Kong, et al.
The Lancet. HIV|May 23, 2025
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adultsRichard L Wu, Katherine V Houser, Martin R Gaudinski, et al.
Cell|May 26, 2015
Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 DonorsTongqing Zhou, Rebecca M Lynch, Lei Chen, et al.
Nature Communications|December 14, 2022
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clonesNoemia S Lima, Maryam Musayev, Timothy S Johnston, et al.
Nature Medicine|February 5, 2020
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorVincent Dussupt, Rajeshwer S Sankhala, Gregory D Gromowski, et al.
Pageof 67